[company_age]unknown[/company_age][employees]2-10 employees[/employees][description]ReNewVax Ltd. is a University of Liverpool spin-out company co-founded by Dr. Marie Yang and Prof. Aras Kadioglu. The company was created through seed funding awarded by Innovate ICURe and funding from the University of Liverpool’s Enterprise Investment Fund. ReNewVax aims to eliminate life-threatening bacterial infections and combat antimicrobial resistance with novel, broad coverage vaccines. The company's lead program, RVX-001, is a potentially first universal vaccine to Streptococcus pneumoniae (or pneumococcus). ReNewVax also has two other vaccine candidates in its pipeline: RVX-002, a vaccine to Streptococcus agalactiae (or GBS), and RVX-003, a vaccine to Streptococcus pyogenes (or GAS). ReNewVax is a relatively new company, having been founded in 2022, but it has already made significant progress in its vaccine development programs. The company has a strong scientific team and has attracted significant investment. ReNewVax is well-positioned to make a significant contribution to the fight against bacterial infections and antimicrobial resistance.[/description][ps]Novel, broad coverage vaccines[/ps]